Italy Fines Apple €98.6 Million Over App Store Dominance 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
SAN DIEGO, Feb. 06, 2017 -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York at 2:30 p.m. ET on Monday, February 13, 2017. An audio webcast and copy of the presentation will be available in the Investors section of the company’s website at www.conatuspharma.com.
About Conatus Pharmaceuticals Inc.
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding emricasan’s potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
MEDIA: David Schull Russo Partners, LLC (858) 717-2310 [email protected] INVESTORS: Alan Engbring Conatus Pharmaceuticals Inc. (858) 376-2637 [email protected]
